Keep up-to-date with the latest access to medicines news and research, plus interviews and opinion from our partners and other experts, and videos and photo stories of our work.
News - Page 25 of 30
-
The Indonesian patent club – and its impact on Hep C treatment
Communities are refusing to accept patent abuse – challenging unmerited patents, and finding ways around them in the meantime. Community...
-
Myanmar: Creating an intellectual property law that protects public health
Lobbying for an intellectual property law that doesn’t just serve big business, but protects public health and encourages innovation in...
-
The Network vs. Abbvie – the first victory in reducing cost of HIV drug
The first victory has been won – and our partner in Ukraine intends to see the case through. On 4...
-
Brazil: 10 years of a Compulsory License on HIV drug Efavirenz
Symposium in Curitiba highlights the need for a collective fight to make medicines affordable. When governments are unreceptive, it is...
-
Patients demand AbbVie’s price bubble is burst – key HIV drug out of reach
AbbVie’s monopoly has hiked prices – it’s time to burst the bubble and get prices back down to earth. Activists...
-
Malaysia paves the way for compulsory licensing on hepatitis C medicines
Historic decision will cure more hepatitis C patients – and other countries can follow suit. Today, 20 September 2017, Malaysia’s...
-
Online access: Training course on reducing barriers to medicines in Africa
Making intellectual property issues easier to understand, to increase access to medicines – and you can apply now! An online...
-
Tackling the hepatitis C epidemic in Malaysia
With new, revolutionary, drugs available, why isn’t everyone getting the cure? An estimated 454,000 people are living with hepatitis C...
-
An important step towards affordable TAF in Ukraine
Gilead adds TAF, a drug used in HIV and Hepatitis B treatment, to the Medicines Patent Pool for Ukraine. It...
-
IAS 2017: Closing ceremony exposes Gilead Sciences
Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” Yesterday, the 9th International AIDS Conference on HIV Science...
-
“We want dolutegravir for all, and we want it now.”
Article first published on the Huffington Post here. We’re calling for a compulsory license on a ‘new’ HIV drug to...
-
A victory for ITPC-MENA : Bristol-Myers Squibb extends its voluntary license on atazanavir to Egypt
During the 9th International AIDS Conference (23-26 July 2017), Bristol-Myers Squibb (BMS) and the Medicines Patent Pool (MPP) announced the...